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Abstract
Background: Inflammatory breast cancer (IBC) is a rare, aggressive breast cancer diagnosed clinically by the presence of diffuse erythema, peau d’orange, and edema that arise quickly in the affected breast. This study evaluated the
validity of medical records in Gharbiah, Egypt in identifying clinical signs/symptoms of IBC. For 34 IBC cases enrolled
in a case–control study at the Gharbiah Cancer Society and Tanta Cancer Center, Egypt (2009–2010), we compared
signs/symptoms of IBC noted in medical records to those recorded on a standardized form at the time of IBC diagnosis by clinicians participating in the case–control study. We calculated the sensitivity and specificity of medical records
as compared to the case–control study for recording these signs/symptoms. We also performed McNemar’s tests.
Results: In the case–control study, 32 (94.1%) IBC cases presented with peau d’orange, 30 (88.2%) with erythema,
and 31 (91.2%) with edema. The sensitivities of the medical records as compared to the case–control study were 0.8,
0.5, and 0.2 for peau d’orange, erythema, and edema, respectively. Corresponding specificities were 1.0, 0.5, and 1.0.
p values for McNemar’s test were <0.05 for all signs. Medical records had data on the extent and duration of signs for
at most 27% of cases for which this information was recorded in the case–control study. Twenty-three of the 34 cases
(67.6%) had confirmed diagnosis of IBC in their medical records.
Conclusion: Medical records lacked information on signs/symptoms of IBC, especially erythema and edema, when
compared to the case–control study. Deficient medical records could have implications for diagnosis and treatment
of IBC and proper documentation of cases in cancer registries.
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Background
Inflammatory breast cancer (IBC) is a rare and aggressive
type of locally advanced breast cancer (LABC) characterized by diffuse erythema and edema (or peau d’orange) of
the breast [1, 2]. The IBC diagnosis is primarily clinical
but also requires pathological confirmation of cancer. It
can be confused with other types of neglected LABC but
is differentiated by the rapid onset of symptoms.
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The definition of IBC according to the seventh edition
of the American Joint Committee on Cancer (AJCC)
Cancer Staging Manual has three requirements: (A) the
presence of diffuse erythema, edema, and peau d’orange
over at least one-third of the breast, and (B) rapid onset
of symptoms, and; (C) a pathologic diagnosis of breast
cancer. There is frequently no underlying tumor mass.
Previous AJCC definitions of IBC have included variable
proportions of breast involvement—from no specified
proportion requirement (AJCC 5th edition) [3] to the
“majority” of the breast (AJCC 6th edition) [4] to onethird of the breast (AJCC 7th edition) [5]. Some countries
have used different definitions of IBC, such as “pousee
evolutive,” which is used in Tunisia [6].
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There is an urgent need to better identify this condition in population-based cancer registries around the
world. In the surveillance, epidemiology and end results
(SEER) database in the United States, IBC is defined by
a combination of histology, stage, and Extent of Disease
(EOD) codes, which accommodate changes in the AJCC
definition over time. These codes are not routinely used
in other population-based cancer registries around the
world, including those in North Africa. Therefore, IBC is
not routinely identified in most population-based cancer
registries. Accurate registration of IBC in populationbased registries requires both a set of codes to capture
the clinical characteristics as well as complete and accurate recording of clinical signs and symptoms of IBC in
routine medical records (MRs) and accommodating for
different definitions to facilitate comparisons from different time periods and locations.
To our knowledge, there have been no previous studies in which the signs of IBC noted in medical records
have been compared to signs/symptoms systematically
recorded at the time of diagnosis by clinicians who have
been specifically trained in the diagnosis of IBC (i.e., a
gold standard). Therefore, this study aimed to evaluate
the validity of medical records from the Nile Delta region
of Egypt in the identification of IBC in the context of an
ongoing case–control study.

Methods
Context: case–control study

Over the past 5 years, an epidemiologic case–control
study was developed and conducted by several of the
co-authors in Egypt, Tunisia, and Morocco to enroll IBC
patients based on clinical evidence and investigate the
epidemiology of the disease. The Tanta Cancer Center
(TCC) and the Gharbiah Cancer Society (GCS) were the
sources of patients for the Gharbiah study site in Egypt.
Patients were recruited and enrolled if (A) they were
female, Egyptian, and at least 18 years old; (B) had erythema and/or edema/peau d’orange in at least one-third
of the breast; (C) did not have extensive ulceration; (D)
had pathologic confirmation of cancer; (E) had no previous treatment for the present breast cancer, and; (F)
had no history of breast cancer. The patients enrolled in
this study were confirmed as IBC using the signs/symptoms present during clinical examinations in addition to
pathological confirmation of cancer. During the period
of 2009–2010, 40 patients were recruited from TCC and
GCS and each case was given a unique study ID number.
Data collection

As part of the case–control study, information on signs
and symptoms associated with diagnosis of IBC was collected at the time of diagnosis on standardized forms
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based on the clinical examination by physicians participating in the case–control study. Information collected
included the presence, extent, and duration of erythema,
peau d’orange, and increase in breast size. In addition,
information was collected on the following signs/symptoms of breast cancer that might be helpful in distinguishing IBC from other types of locally advanced breast
cancer that are characterized by neglect and delayed
diagnosis: the presence, size, and duration of a palpable
mass, ulceration, and palpable axillary lymph nodes.
Abstraction forms were developed and used to identify
possible IBC cases from medical records of the 2 study
hospitals (TCC and GCS) during the same time period
as the case–control study (2009–2010). The medical
records collected included all patients who received neoadjuvant chemotherapy for breast cancer treatment at
the same institutions. The same variables collected in the
case–control study were included in the medical record
abstraction.
Data analysis

Data analysis focused on: (A) identifying the IBC cases
included in the case–control study who had medical records available; (B) identifying the concordance
between the signs/symptoms collected for the case–
control study and the signs/symptoms recorded on the
routine medical records; (C) calculating sensitivity and
specificity for signs recorded in the medical records compared to those recorded for the case–control study, and;
(D) performing McNemar’s tests for each symptom to
determine if there was a significant difference between
the two data sources, taking into account the paired
nature of the data. A p value less than 0.05 suggested
significant discordance. In this study, peau d’orange and
edema were combined and analyzed together as peau
d’orange. Similarly, erythema and inflammation were
combined and analyzed as erythema. All statistical analysis was performed using SAS 9.2 (Cary, NC).
Medical records were available for 34 (85%) of the 40
cases that were recruited in the case–control study. The
6 remaining cases did not have medical records from
GCS or TCC due to receiving treatment elsewhere. There
were a number of additional variables abstracted from
the medical records that were excluded from analysis
in the present study, including the name of the examining physician for each patient, which is referenced in the
discussion. The study was approved by the University of
Nebraska Medical Center IRB Committee (Protocol 06013-EX) and the Gharbiah Cancer Society IRB Committee in Egypt. No patients were approached for this study
and the secondary analysis of data of the medical records
did not include any data of children. The consent was
waived by the IRB Committees listed above in Egypt and
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Nebraska because of the secondary analysis of the aggregate data of the study.

Results
Twenty-three of the 34 cases (67.6%) had confirmed IBC
diagnosis in their medical records. According to case–
control study, 30 (88.2%) of the 34 patients recruited
presented with peau d’orange, 30 (88.2%) presented with
erythema, and 31 (91.2%) with an increase in breast size.
In the medical records, 24 (70.6%) were recorded as having peau d’orange, 18 (52.9%) as having erythema, and 7
(20.6%) as having an increase in breast size (Table 1). Further, case–control data on the size/extent and duration of
peau d’orange was available for 29 (85.3%) and 24 (70.6%)
of the 34 cases, respectively, whereas the same information was available for only 8 (23.5%) and 9 (26.5%) of the
34 cases, respectively, in the medical records. For erythema, information on extent and duration was available
for 30 (88.2%) and 23 (67.6%) cases, respectively. In the
medical records, the same information was recorded for
7 (20.6%) and 16 (47.1%) cases. Data regarding the extent
of increase in breast size were available for 31 (91.2%)
cases; 24 (70.6%) cases had information on duration
of increase in breast size. Only 1 case from the medical records had information on the extent of increase in
breast size, and 7 (20.6%) cases had information on duration of the symptom.
As shown in Table 2, peau d’orange had the highest
sensitivity (80%) of the 3 signs and edema the lowest
(0.22). Peau d’orange and edema had specificities of 100%,
Table 1 Comparison of information available on the presence, extent, and duration of peau d’orange and erythema
in the case–control study and in medical records (N = 34)
Case–control study

MR

Presence

30 (88.2%)

24 (70.6%)

Extent

29 (85.3%)

8 (23.5%)

Duration

24 (70.6%)

9 (26.5%)

Presence

30 (88.2%)

18 (52.9%)

Extent

30 (88.2%)

7 (20.6%)

Duration

23 (67.6%)

16 (47.1%)

Sign
Peau d’orangea,b

Erythemaa,c

Increase in breast sizea
Presence

31 (91.2%)

7 (20.6%)

Extent

31 (91.2%)

1 (2.9%)

Duration

24 (70.6%)

7 (20.6%)

This table excludes the 6 cases that lacked medical record data
a

Symptoms are not mutually exclusive

b

Peau d’orange and/or Edema

c

Erythema and/or inflammation

but results were based on very small sample sizes. Peau
d’orange, erythema, and increase in breast size all had
significant p-values (0.014, 0.0027, p < 0.0001, respectively) for the McNemar’s test. Only 5 cases had complete
information in the medical records on presence, extent,
and duration of erythema, peau d’orange, and edema/
increase in breast size.
Table 3 lists other signs that were also recorded in the
case–control study. Presence of a palpable mass was
recorded for 27 cases (79.4%) by clinicians participating
in the case–control study, slight ulcerations for 5 cases
(14.7%), and palpable axillary lymph nodes for 28 (82.4%)
cases. Sensitivities for all three signs were around 0.60
and specificities especially high for ulceration (0.97) and
palpable lymph nodes (0.83). McNemar’s test for presence of a palpable mass and ulceration were not statistically significant (0.07 and 0.56, respectively).

Discussion
Our results suggest that there are serious limitations in
the recording of signs and symptoms needed for the diagnosis of inflammatory breast cancer according to AJCC
[5, 7] criteria in the medical records of the Tanta Cancer Institute and the Gharbiah Cancer Society in Tanta,
Egypt. This was particularly true for erythema and for
the extent and duration of all three signs (erythema, peau
d’orange, and increase in breast size).
There may be a variety of reasons why examining physicians would fail to report all IBC signs and symptoms
in patient medical records. IBC is a rare type of breast
cancer and is not well understood by physicians in many
places. For example, some physicians lack education
regarding IBC diagnoses, as is the case among primary
care physicians in Egypt and Tunisia [8]. This could be
due to a paucity of emphasis on oncology during medical
school, the fragmentation of cancer-focused education
at both the undergraduate and graduate level, and the
absence of continuing medical education post-graduation
[9, 10].
Previous studies have found that physicians often fail
to obtain or access continuing medical education (CME)
modules, especially in developing countries, which
thereby affects their knowledge regarding new cancer
epidemiology and accurate cancer diagnosis and management [8, 11–13]. CME is necessary to keep health professionals up to date as the IBC definition evolves. There
also needs to be increased emphasis on the standardization of these cancer-focused education programs across
institutions.
Strengths of this study included the use of a separate,
ongoing case–control study as a gold standard. The
case–control study was conducted by IBC-trained physicians who recruited patients based on a clinical exam
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Table 2 Comparison of symptoms required for IBC, as recorded in the case–control study (N = 34) versus in medical
records for patients recruited in the NAS
Peau d’orangea

Erythemab

Increase in breast size

Case–control study

Case–control study

Case–control study

Yes

No

Yes

No

Yes

No

Medical records
Yes

24

0

16

2

7

0

No

6

4

14

2

24

3

Sensitivity = 0.8

Sensitivity = 0.53

Sensitivity = 0.22

Specificity = 1.0

Specificity = 0.5

Specificity = 1.0

p = 0.014

p = 0.0027

p < 0.0001

This table excludes the 6 cases from the case–control study that had no medical records
p-values are derived from McNemar’s tests
a

Edema and/or Peau d’Orange

b

Erythema and/or inflammation

Table 3 Comparison of additional symptoms as recorded in the case–control study (N = 34) versus in medical records
for the same patients
Presence of palpable mass

Ulceration

Palpable axillary lymph nodes

Case–control study

Case–control study

Case–control study

Yes

No

Yes

No

Yes

No

Medical records
Yes

16

4

3

1

16

1

No

11

3

2

28

12

5

Sensitivity = 0.59

Sensitivity = 0.6

Sensitivity = 0.57

Specificity = 0.43

Specificity = 0.97

Specificity = 0.83

p = 0.07

p = 0.56

p = 0.0023

This table excludes the 6 cases from the case–control study that had no medical records
p-values are derived from McNemar’s tests

and recorded thorough information on the signs and
symptoms present using standardized forms, allowing for
comparison with medical record data. Limitations of this
study include the relatively small number of IBC cases
and variability in diagnoses due to the number of physicians examining patients (N = 19, data not shown).

Conclusions
This study revealed deficits in the information recorded
on medical records needed to identify IBC cases. Deficient medical record information could negatively impact
the diagnosis and treatment for IBC patients. Furthermore, deficient medical record information could affect
the perceived prevalence of IBC and limit the ability
to record IBC cases in cancer registries, which would
thereby hinder the study of its management and prevention epidemiology. Our findings support the need for a

universal definition of IBC to help improve the reliability of medical records for registry-based research or ways
to accommodate for multiple definitions to facilitate IBC
research in developing countries. Future studies should
compare other Egyptian institutions as well as neighboring developing countries to determine the most appropriate method of maintaining medical records for reliably
identifying IBC cases. Additionally, improvements in
professional education regarding the symptoms and clinical characteristics of IBC would allow future professionals to correctly diagnose true IBC cases as such and stay
up to date upon diagnostic criteria and state of the art
research surrounding IBC. International registries should
also explore a standardized procedure for identifying and
registering IBC cases.
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